Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses

BACKGROUND: Most immunotherapies approved for clinical use rely on the use of recombinant proteins and cell-based approaches, rendering their manufacturing expensive and logistics onerous. The identification of novel small molecule immunotherapeutic agents might overcome such limitations. METHOD: Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shuai, Zhao, Liwei, Guo, Mengfei, Liu, Peng, Li, Sijing, Xie, Wei, Tian, Ai-Ling, Pol, Jonathan G, Chen, Hui, Pan, Hui, Mao, Misha, Li, Yumei, Zitvogel, Laurence, Jin, Yang, Kepp, Oliver, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347457/
https://www.ncbi.nlm.nih.gov/pubmed/37419511
http://dx.doi.org/10.1136/jitc-2023-006785

Ejemplares similares

Ejemplares similares